Does personalized medicine cut the mustard when it comes to treating cancer? Richard Smith, a former editor of the British Medical Journal, believes that it does not. Using the mustard metaphor, he shows how personalized medicine undermines the pharmaceutical industry’s profits. If the one-size-fits-all approach to prescribing cancer drugs were abandoned, drug companies would be forced to change their business model, most notably by increasing prices radically – or stop producing the drugs altogether.
View the original article here: Personalized Medicine’s Perverse Economics
Personalized medicine’s perverse economics
Donna Dickenson | Project Syndicate | December 21, 2012
{{ reviewsTotal }}{{ options.labels.singularReviewCountLabel }}
{{ reviewsTotal }}{{ options.labels.pluralReviewCountLabel }}
{{ options.labels.newReviewButton }}
{{ userData.canReview.message }}
GLP Podcasts & Podcast Videos | More... |
Infographics | More... |
Infographic: Could gut bacteria help us diagnose and treat diseases? This is on the horizon thanks to CRISPR gene editing
Humans are never alone. Even in a room devoid of other people, they are always in the company of billions ...
Most Popular
- Is tilapia a human-made freak that we should avoid — or an evolutionary rockstar?
- Viewpoint: Debunking organic food myths again… and again
- 25 years of GMO crops: Economic, environmental and human health benefits
- Viewpoint: The organic food industry is a $180 billion marketing fraud
- How Wegovy and Ozempic could transform our food systems
- Marrying your cousin? There may be evolutionary benefits
- Close cousins: Just 400,000 years ago, modern humans and Neanderthal lineages split, 100,000 years more recently than previous estimates
- Embryos aren’t female by ‘default’ after all, study shows
- Why is it so difficult to find a treatment for Huntington’s Disease?
- Brewing resistance: Studying coffee’s genetic lineage provides clues on how to create varieties to survive climate change